Showing results (821-830 of 1,019) with videos related to

Sort By:
Pageof 102
Clinicoeconomics and Outcomes Research : CEOR|November 22, 2019
Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular AtrophyAndrew J Lloyd, Robin Thompson, Katy Gallop, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 26, 2019
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature reviewAnna Forsythe, Christina S Kwon, Timothy Bell, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 5, 2018
Erratum: Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region [Corrigendum]
Clinicoeconomics and Outcomes Research : CEOR|December 5, 2018
Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical riskMassimiliano Povero, Antonio Miceli, Lorenzo Pradelli, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 29, 2020
A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with SeropositivitySang Hee Park, Xue Han, Francis Lobo, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 12, 2020
Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching AnalysisVladimir Zah, Jovana Pelivanovic, Simona Tatovic, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 2, 2020
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature ReviewsLauren J Lee, Christina S Kwon, Anna Forsythe, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 12, 2018
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in SpainElena Galve-Calvo, Eva González-Haba, Joana Gostkorzewicz, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 12, 2018
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspectiveDhvani Shah, Nancy A Risebrough, Johnna Perdrizet, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 12, 2018
Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapiesCheryl P Ferrufino, Julie Munakata, Wenhui Wei, et al.
Pageof 102